Additional drugmakers flag risks of working with WuXi amid heightened US scrutiny

More drug companies are disclosing the potential for clinical trial delays and drug shortages if the US government blacklists a family of WuXi companies used across the biopharma industry.

The disclosures come from companies large and small, including Merck, Cabaletta Bio and Kyverna Therapeutics. Through securities filings, Endpoints News identified nearly three dozen companies that rely on WuXi and have flagged the risk of a crackdown. The tally is more than double since March 13, when Endpoints first compiled a list of potentially affected companies.

Kyverna, for example, said in a filing that WuXi is the sole provider of cell manufacturing and testing for its lead program, KYV-101. Last month, Kyverna raised $319 million in a public offering to test the cell therapy in Lupus and other conditions. In the March 26 filing, Kyverna said finding manufacturing alternatives could result in “increased costs and impair our ability…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks